Article
Pfizer's hemophilia therapy reduces bleeding in late-stage study
Rating:
0.0
Views:
57
Likes:
1
Library:
1
U.S. drugmaker Pfizer Inc said on Tuesday late-stage study data for its experimental hemophilia therapy showed superiority to the current standard of care treatment in reducing bleeding rates in patients.
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value